Biomarin Pharmaceutical (BMRN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Simply Wall St11:41 ET
Worst Performing Stocks for Tax Loss Selling – Wolfe
Seeking AlphaDec 16 14:59 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $90 Price Target
BenzingaDec 12 11:47 ET
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Yahoo FinanceDec 11 05:14 ET
11 Compounder Opportunities According to Goldman: AMD, BDX, INFA
Seeking AlphaDec 5 13:26 ET
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $101
Moomoo NewsDec 5 11:31 ET · Ratings

Comments

Moomoo AI

Mar 25 07:52

Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.

Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness

1

Moomoo AI

Mar 7 07:41

BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.

Press Release: BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

1

Moomoo AI

Feb 8 08:52

BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Is Matching Sentiment Around Its Revenues

1

Moomoo AI

Jan 18 06:34

BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Moomoo AI

Dec 21, 2023 10:14

Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.

BioMarin May Be More of an M&A Target With Activist Elliott Pact - Analysts

BMRN Biomarin Pharmaceutical

Trade Overview

Capital Trend

News

Comments